Ovarian Cancer

>

Latest News

FDA Clears IND of BAT8006 in Platinum-Resistant Ovarian Cancers
FDA Clears IND of BAT8006 in Platinum-Resistant Ovarian Cancers

March 25th 2024

A phase 2 trial plans to evaluate BAT8006 for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

McHale Analyzes the Benefits and Challenges of PARP Inhibition for Certain Patients With Advanced Ovarian Cancer
McHale Analyzes the Benefits and Challenges of PARP Inhibition for Certain Patients With Advanced Ovarian Cancer

March 23rd 2024

FDA Grants Full Approval to Mirvetuximab for Platinum-Resistant Ovarian Cancer
FDA Grants Full Approval to Mirvetuximab for Platinum-Resistant Ovarian Cancer

March 22nd 2024

Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC

March 22nd 2024

ctDNA Provides Guidance for Therapy Options in Epithelial Ovarian Cancer
ctDNA Provides Guidance for Therapy Options in Epithelial Ovarian Cancer

March 20th 2024

Video Series
Video Interviews

More News